Granted Patent B2

US 10,188,710 · App. 14/547,981 · Granted Jan 29, 2019

Inventors: Phyllis Losikoff (Sharon, MA); Stephen Gregory (Providence, RI); Anne DeGroot (Providence, RI); William Martin (Cumberland, RI)

Assignee: Rhode Island Council on Postsecondary Education

A61K39/0005A61K39/0008C07K14/005A61K38/00A61K2039/5256A61K2039/57A61K2039/577C12N2770/24222C12N2770/24234

Abstract

Claims (13)

1. A pharmaceutical composition comprising an isolated T-cell epitope peptide adapted to repress an immune response and a pharmaceutically acceptable carrier or excipient; said peptide consists of an amino acid sequence of PLLLLLLXLPXRA (SEQ ID NO:5), wherein X is an amino acid and does not have to be the same amino acid in each occurrence in a given sequence.

2. The pharmaceutical composition of claim 1 , wherein the PLLLLLLXLPXRA peptide is selected from the group consisting of PLLLLLLSLPPRA (SEQ ID NO:2) and PLLLLLLALPQRA (SEQ ID NO:6).

3. The pharmaceutical composition of claim 1 , further comprising a target antigen.

4. An isolated T-cell epitope peptide, consisting of an amino acid sequence of PLLLLLLXLPXRA (SEQ ID NO:5), wherein X is an amino acid and does not have to be the same amino acid in each occurrence in a given sequence.

5. The T-cell epitope peptide of claim 4 , wherein the PLLLLLLXLPXRA sequence is selected from the group consisting of PLLLLLLSLPPRA (SEQ ID NO:2) and PLLLLLLALPQRA (SEQ ID NO:6).

6. A nucleic acid encoding the T-cell epitope peptide of claim 5 .

7. A vector comprising the nucleic acid of claim 6 .

8. An isolated cell comprising the vector of claim 7 .

9. A pharmaceutical composition comprising an isolated T-cell epitope peptide adapted to repress an immune response and a pharmaceutically acceptable carrier or excipient; wherein said peptide is 13-25 amino acids long and comprises a sequence of PLLLLLLXLPXRA (SEQ ID NO:5), wherein X is an amino acid and does not have to be the same amino acid in each occurrence in a given sequence, provided that said peptide does not contain PLLLLLLALPQRA (SEQ ID NO:6).

10. The pharmaceutical composition of claim 9 , wherein the PLLLLLLXLPXRA sequence is PLLLLLLSLPPRA (SEQ ID NO:2).

11. The pharmaceutical composition of claim 9 , further comprising a target antigen.

12. The pharmaceutical composition of claim 10 , further comprising a target antigen.

13. The pharmaceutical composition of claim 2 , further comprising a target antigen.

Assignments (8)

Continuity (2)